Taxane response in prostate cancer may not be influenced by androgen receptor variations

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma

Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma

Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma

Impact of statins on survival outcomes in metastatic renal cell carcinoma

Genomic profiling may reveal new drug targets in urothelial carcinoma

Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer

Management after radical prostatectomy: early adjuvant radiotherapy or wait-and-see?

Is there a role for androgen deprivation therapy combined with radiotherapy in intermediate risk prostate cancer?

When and whether to conduct endocrine therapy in non-metastatic prostate cancer